Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Wall Street Opens Lower as Today's Lockdowns Overshadow Tomorrow's Cures

Published 08/12/2020, 14:44
Updated 08/12/2020, 14:46
© Reuters.
US500
-
DJI
-
PFE
-
TSLA
-
IXIC
-
MRNA
-
UBER
-
BNTX
-

By Geoffrey Smith 

Investing.com -- U.S. stock markets opened modestly lower on Tuesday, paring premarket losses after the Food and Drug Administration indicated it was ready to approve the Pfizer/BioNTech vaccine for emergency use later this week. 

Prior to the release of the FDA's analysis of data from the two companies' stage three trial of their Covid-19 vaccine, markets had been indicated down by more, a response to fresh evidence that the pandemic is effectively still running out of control in much of the U.S.

By 9:45 AM ET (1545 GMT), the Dow Jones Industrial Average was down 20 points, or 0.1% at 30,049, while the S&P 500 was down 0.3% and the NASDAQ Composite was down 0.4%.

Among early movers, Tesla (NASDAQ:TSLA) stock, which had soared another 7% on Monday to a new record high, fell 2.0% in response to the news that the company planned to raise up to $5 billion via an equity distribution scheme that would see it dribble stock out into the market over an extended time.

Pfizer (NYSE:PFE) stock rose 1.1% and BioNTech (NASDAQ:BNTX) stock rose 2.2% to another new record high after the FDA’s data dump acknowledged that their drug “met the prescribed success criteria” for treating Covid-19. The FDA committee responsible for authorizing new medicines meets on Thursday to take a decision on authorizing the vaccine for emergency use.

Moderna (NASDAQ:MRNA) stock rose 4.7% on hopes that its drug, which employs the same biological technology as the Pfizer/BioNTech one, will also soon be approved.

The FDA news comes against a backdrop of tightening restrictions on business and social life across the U.S., as the numbers of dead and hospitalized with the virus continue to break records. Over the last week, an average 2,204 American have died of the coronavirus, while the number of those admitted to hospital has risen above 102,000 for the first time, according to the Covid Tracking Project.

Elsewhere, Uber (NYSE:UBER) stock fell 2.1% after the ride-hailing company paid $400 million to autonomous driving startup Aurora to take its own self-driving technology operations off its hands, the latest in a string of money-losing businesses that Uber has shed this year as it struggles to move toward profitability. The company will take a 26% stake in Aurora in return, and thus keep some upside exposure. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.